Lixte Biotechnology Holdings, Inc. cash flow to debt ratio of -462.10% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Lixte Biotechnology Holdings, Inc.'s free cash flow has increased -2.97% from $-3.16M last year to $-3.07M, signaling increasing performance

Lixte Biotechnology Holdings, Inc.'s debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Lixte Biotechnology Holdings, Inc. has insufficient data to evaluate this check.

Lixte Biotechnology Holdings, Inc. has negative EBITDA, making leverage ratio unreliable

Lixte Biotechnology Holdings, Inc.'s interest coverage ratio is -700.53, which means that the company struggles to meet interest obligations, signaling financial risk.

Lixte Biotechnology Holdings, Inc. has insufficient data to evaluate this check.

Lixte Biotechnology Holdings, Inc.'s short-term assets of $5.18M exceed its short-term liabilities of $1.33M

Lixte Biotechnology Holdings, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Lixte Biotechnology Holdings, Inc.'s return on equity of -125.56%, is lower than 15.00%, indicating bad performance

Lixte Biotechnology Holdings, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Lixte Biotechnology Holdings, Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Lixte Biotechnology Holdings, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Lixte Biotechnology Holdings, Inc. has negative free cash flow, indicating cash burn

Lixte Biotechnology Holdings, Inc.'s yearly earnings has decreased 67.58% since last year from $-3.59M to $-6.01M, signaling decreasing performance

Lixte Biotechnology Holdings, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -62.41% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Lixte Biotechnology Holdings, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Lixte Biotechnology Holdings, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Lixte Biotechnology Holdings, Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Lixte Biotechnology Holdings, Inc. has insufficient data to evaluate this check.

Lixte Biotechnology Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lixte Biotechnology Holdings, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Lixte Biotechnology Holdings, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Lixte Biotechnology Holdings, Inc. has insufficient data to evaluate this check.

Lixte Biotechnology Holdings, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Lixte Biotechnology Holdings, Inc. has a price-to-book ratio of 9.85x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Lixte Biotechnology Holdings, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue